These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 17695430)

  • 1. A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study).
    Kodera Y; Ito S; Mochizuki Y; Fujitake S; Koshikawa K; Kanyama Y; Matsui T; Kojima H; Takase T; Ohashi N; Fujiwara M; Sakamoto J; Akimasa N;
    Anticancer Res; 2007; 27(4C):2667-71. PubMed ID: 17695430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer.
    Kim JG; Sohn SK; Song HS; Kwon KY; Do YR; Lee KH; Hyun MS; Ryoo HM; Bae SH; Park KU; Baek JH; Lee WS; Chung JS; Cho GJ; Sohn CH; Jang JS; Chung HY; Yu W
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):863-9. PubMed ID: 17333192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer: Korea Japan Collaborative Study Group Trial.
    Kim YH; Yamaguchi K; Bang YJ; Takiuchi H; Kang WK; Sato A; Kang YK; Sakamoto J; Abe C; Sakata Y
    Jpn J Clin Oncol; 2007 Jul; 37(7):501-8. PubMed ID: 17673470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of weekly paclitaxel as a second-line treatment for S-1-refractory advanced gastric cancer.
    Matsuda G; Kunisaki C; Makino H; Fukahori M; Kimura J; Sato T; Oshima T; Nagano Y; Fuii S; Takagawa R; Kosaka T; Ono HA; Akiyama H; Ichikawa Y
    Anticancer Res; 2009 Jul; 29(7):2863-7. PubMed ID: 19596975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial.
    Koizumi W; Akiya T; Sato A; Yamaguchi K; Sakuyama T; Nakayama N; Tanabe S; Higuchi K; Sasaki T; Sekikawa T;
    Jpn J Clin Oncol; 2009 Nov; 39(11):713-9. PubMed ID: 19812061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
    Lee SJ; Cho SH; Yoon JY; Hwang JE; Bae WK; Shim HJ; Chung IJ
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):159-66. PubMed ID: 19479256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer.
    Inada S; Tomidokoro T; Fukunari H; Sato T; Hatano T; Nishimura A; Kawauchi Y; Nikkuni K; Shimizu T; Sato T; Yanagi M; Takahashi S; Yoshida H; Sugita M; Hayashi T
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):267-73. PubMed ID: 18379784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-center phase II trial of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric and gastro-esophageal cancer.
    Sun Q; Liu C; Zhong H; Zhong B; Xu H; Shen W; Wang D
    Jpn J Clin Oncol; 2009 Apr; 39(4):237-43. PubMed ID: 19264768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Feasibility study of weekly paclitaxel as second-line chemotherapy against 5-FU-refractory gastric carcinoma].
    Ito S; Kodera Y; Mochizuki Y; Yamamura Y
    Gan To Kagaku Ryoho; 2005 Oct; 32(10):1427-30. PubMed ID: 16227742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
    Pignata S; Breda E; Scambia G; Pisano C; Zagonel V; Lorusso D; Greggi S; De Vivo R; Ferrandina G; Gallo C; Perrone F
    Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer.
    Gu Y; Shu Y; Xu Q
    Biomed Pharmacother; 2009 May; 63(4):293-6. PubMed ID: 18848761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Usefulness of weekly administration of paclitaxel for advanced or recurrent gastric cancer].
    Egawa T; Kubota T; Nagashima A; Doi M; Kitano M; Hayashi S; Yoshii H; Saikawa Y; Kitajima M
    Gan To Kagaku Ryoho; 2004 Jun; 31(6):877-81. PubMed ID: 15222104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel and carboplatin in pretreated advanced gastric cancer: a phase II study.
    Stathopoulos GP; Rigatos SK; Fountzilas G; Polyzos A; Stathopoulos JG
    Oncol Rep; 2002; 9(1):89-92. PubMed ID: 11748462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase i study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer.
    Matsubara J; Shimada Y; Takashima A; Takahari D; Hirashima Y; Okita NT; Nakajima TE; Kato K; Hamaguchi T; Yamada Y; Shirao K
    Jpn J Clin Oncol; 2008 Aug; 38(8):540-6. PubMed ID: 18628316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Low-dose paclitaxel therapy as second-line chemotherapy for patients who previously received TS-1 therapy].
    Takemura M; Osugi H; Lee S; Kaneko M; Tanaka Y; Fujiwara Y; Nishizawa S; Iwasaki H
    Gan To Kagaku Ryoho; 2004 Dec; 31(13):2183-6. PubMed ID: 15628768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer.
    Nakajo A; Hokita S; Ishigami S; Miyazono F; Etoh T; Hamanoue M; Maenohara S; Iwashita T; Komatsu H; Satoh K; Aridome K; Morita S; Natsugoe S; Takiuchi H; Nakano S; Maehara Y; Sakamoto J; Aikou T;
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1103-9. PubMed ID: 18317763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.
    Penel N; Bui BN; Bay JO; Cupissol D; Ray-Coquard I; Piperno-Neumann S; Kerbrat P; Fournier C; Taieb S; Jimenez M; Isambert N; Peyrade F; Chevreau C; Bompas E; Brain EG; Blay JY
    J Clin Oncol; 2008 Nov; 26(32):5269-74. PubMed ID: 18809609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase II study comparing dose escalated weekly paclitaxel vs. standard dose weekly paclitaxel for patients with previously treated advanced gastric cancer.
    Shitara K; Oze I; Mizota A; Kondo C; Nomura M; Yokota T; Takahari D; Ura T; Yuki S; Komatsu Y; Matsuo K; Muro K
    Jpn J Clin Oncol; 2011 Feb; 41(2):287-90. PubMed ID: 21068025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of weekly paclitaxel in advanced hormone-refractory prostate cancer.
    Chiappino I; Destefanis P; Addeo A; Galetto A; Cucchiarale G; Munoz F; Zitella A; Ferrando U; Fontana D; Ricardi U; Tizzani A; Bertetto O
    Am J Clin Oncol; 2007 Jun; 30(3):234-8. PubMed ID: 17551298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of weekly paclitaxel for advanced or metastatic breast cancer in Japan.
    Horiguchi J; Rai Y; Tamura K; Taki T; Hisamatsu K; Ito Y; Seriu T; Tajima T
    Anticancer Res; 2009 Feb; 29(2):625-30. PubMed ID: 19331212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.